Pfizer recently announced the results obtained from one of its Phase III studies that evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine also known as 20vPnc.
The 20 serotypes included in 20vPnC are responsible for the majority of currently circulating pneumococcal disease in the U.S. and globally.
The primary immunogenicity goal of non-inferiority for the 20 serotypes included in 20vPnC in adults 60 years of age and older at one month after vaccination were met for all serotypes in common with licensed Prevnar 13 and six of the seven additional serotypes when compared to a licensed pneumococcal polysaccharide vaccine, one of the new seven serotypes missed noninferiority criteria by a small margin.
Secondary immunogenicity objectives for adults 18-59 years old compared to those 60-64 years old met non-inferiority for all 20 serotypes.
The safety objectives were met in adults 18 years of age or older demonstrating that the safety and tolerability of 20vPnC were comparable to licensed pneumococcal vaccines.
Pfizer’s 20vPnC vaccine candidate includes 13 serotypes already included in Prevnar 13.
The seven new serotypes included in 20vPnC are global causes of invasive pneumococcal disease , and are associated with high case-fatality rates, antibiotic resistance and/or meningitis.
Pneumococcal pneumonia is estimated to cause about 500,000 deaths in adults 70 years and older every year, around the world.